Two complementary preclinical advances outline strategies to insert gene‑sized payloads without provoking fatal innate immune reactions. One team described 'stealth' circular single‑stranded DNA donors that evade cytosolic DNA sensors while preserving recombinase compatibility; another group introduced INSTALL, a nucleus‑synthesized template approach that supports kilobase integrations delivered by LNPs in mouse liver with improved safety profiles. The work was published in high‑impact journals and presented as a pathway to scale genome‑writing therapies beyond single‑mutation edits. Large‑payload integration has been limited by immune sensing of double‑stranded donors; these techniques reduce that barrier and broaden the therapeutic scope for disorders caused by many distinct mutations across a gene. Sponsors developing recombinase‑ and LNP‑based strategies will likely accelerate translational studies to evaluate durability and off‑target risk.